PDCD1 and head and neck squamous cell carcinoma: PD-1/PD-L1 monoclonal antibodies, like pembrolizumab as well as nivolumab, which block immune checkpoint pathways, have become the treatment options for recurrent or metastatic HNSCC [6,35].